Congressional Report: FDA Broke Own Protocols in Approving Biogen Alzheimer's Drug

The FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was 'rife with irregularities,' a congressional report showed on Thursday.
Reuters Health Information

source https://www.medscape.com/viewarticle/986319?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension